Valeant Pharmaceuticals International Inc. revealed during its third quarter sales and earnings call Nov. 8 that a key pipeline product, the IL-17 blocker Siliq (brodalumab) for plaque psoriasis, has been delayed by FDA.
CEO Joseph Papa said the user fee date for the biologics license application (BLA), pending at FDA, has been pushed...







